AR and prostate carcinoma: To determine the role of the androgen analog, R1881, on the expression of MALT1 in AR-positive prostate cancer cells, we treated two ARFL-positive prostate cancer cells, LNCaP and 22Rv1, with various concentrations of R1881 for 24 h.